The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | UVEA-IXA: exploring the use of ixazomib-based therapy in R/R myeloma outside of clinical trials
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, shares results from the UVEA-IXA study, which explored the safety and efficacy of ixazomib-based therapy in patients with relapsed/refractory multiple myeloma (R/R MM) outside of a clinical trial setting. The study highlighted a 67% overall response rate (ORR) and a progression-free survival (PFS) of 15.6 months. Moreover, the therapy was well-tolerated and easily administered. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
